transplant

FDA clears Takeda drug for post-transplant CMV infections

Takeda has scored the first-ever FDA approval of a treatment for refractory cytomegalovirus (CMV) infections in organ transplant patients, which can lead to an increased risk of complications and even death. Livtencity (maribavir) has been cleared for use in transplant patients aged 12 or over with CMV infections that do not respond to first-line treatment …

FDA clears Takeda drug for post-transplant CMV infections Read More »

Talaris therapy ends need for immune drugs in transplant patients

Two kidney transplant patients who received a stem cell therapy developed by Talaris Therapeutics were able to come off all immunosuppressant drugs within a year, without any evidence of graft rejection. The first findings from Talaris’ phase 3 trial of the cell therapy – called FCR001 – suggest it may be possible to eliminate the …

Talaris therapy ends need for immune drugs in transplant patients Read More »

Vifor, Angion organ damage drug fails phase 3 kidney transplant study

Vifor Pharma and partner Angion Biomedica have suffered another setback with their drug to prevent organ damage, this time in high-risk kidney transplant patients. A phase 3 trial of ANG-3777 revealed that it was unable to improve eGFR – a measure of kidney function – compared to placebo in people who received a kidney transplant …

Vifor, Angion organ damage drug fails phase 3 kidney transplant study Read More »

FDA panel backs Takeda’s CMV drug for transplant patients

Takeda is closing on a first FDA approval in the treatment of refractory cytomegalovirus (CMV) infections in organ transplant patients, after agency advisors voted unanimously in favour of its antiviral maribavir. Maribavir (TAK-620) should be approved for refractory CMV infections in people with solid organ transplants as well as haematopoietic stem cell transplants (HSCT), regardless …

FDA panel backs Takeda’s CMV drug for transplant patients Read More »

Novartis’ transplant drug hope iscalimab flunks mid-stage trial

Novartis hopes of improving on tacrolimus as the standard drug for preventing organ rejection in transplant patients have been dashed after its iscalimab candidate failed a mid-phase trial. An interim analysis of data from the CIRRUS-1 trial suggested that iscalimab (CFZ533) was less effective than tacrolimus at preventing rejection in kidney transplant patients when both …

Novartis’ transplant drug hope iscalimab flunks mid-stage trial Read More »